Option Care Health (OPCH) AI Stock Analysis

Company Guidance

Management reaffirmed full-year 2026 guidance of $5.675–$5.775 billion in revenue, adjusted EBITDA of $480–$495 million, and adjusted EPS of $1.85–$1.92, with net interest expense of $50–$55 million, a tax rate of 26–28%, and an operating cash flow target of at least $320 million; Q3 is expected to show sequential revenue growth in the low- to mid-single digits and sequential EBITDA growth in the mid-single-digit range (seasonality consistent with prior years, with H2 stronger). In Q2 the company posted $1.4 billion revenue (+2% YoY, +7% QoQ), $117.5 million adjusted EBITDA (+3% YoY, +12% QoQ), adjusted EPS $0.45 (+$0.04 YoY), operating cash flow $184 million, net debt leverage 2.1x, repurchased $150 million (~5% of shares) leaving $525 million buyback authorization, SG&A ~11% of revenue (-3% YoY), and gross profit dollars up 2% sequentially; they continue to expect ~600 bps of 2026 revenue headwinds from CID and ~$55 million gross profit headwinds, Stelara/biosimilars to be <1% of 2026 net revenue/gross profit, added five infusion clinics (visits +20% YoY), operate >190 facilities, and recorded >35% of nursing visits in suites/clinics.